Bristol-Myers bulks up cancer portfolio with $74 billion Celgene deal


Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, creating a major pharma company with several blockbuster cancer drugs as competition in the immunotherapy space heats up.